1. Home
  2. FTFT vs JAGX Comparison

FTFT vs JAGX Comparison

Compare FTFT & JAGX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Future FinTech Group Inc.

FTFT

Future FinTech Group Inc.

HOLD

Current Price

$1.52

Market Cap

6.2M

ML Signal

HOLD

Logo Jaguar Health Inc.

JAGX

Jaguar Health Inc.

HOLD

Current Price

$0.34

Market Cap

5.0M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
FTFT
JAGX
Founded
N/A
2013
Country
Hong Kong
United States
Employees
N/A
N/A
Industry
Business Services
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
6.2M
5.0M
IPO Year
2008
2014

Fundamental Metrics

Financial Performance
Metric
FTFT
JAGX
Price
$1.52
$0.34
Analyst Decision
Strong Buy
Analyst Count
0
1
Target Price
N/A
$60.00
AVG Volume (30 Days)
148.4K
476.7K
Earning Date
05-19-2026
04-07-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
82.42
EPS
N/A
N/A
Revenue
$3,829,805.00
$11,511,000.00
Revenue This Year
N/A
$61.58
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
77.46
N/A
52 Week Low
$0.56
$0.31
52 Week High
$4.03
$13.25

Technical Indicators

Market Signals
Indicator
FTFT
JAGX
Relative Strength Index (RSI) 57.79 33.46
Support Level $1.52 $0.33
Resistance Level $1.70 $0.46
Average True Range (ATR) 0.21 0.04
MACD 0.01 0.00
Stochastic Oscillator 57.37 0.09

Price Performance

Historical Comparison
FTFT
JAGX

About FTFT Future FinTech Group Inc.

Future FinTech Group Inc is engaged in the financial technology business. The company participates in supply chain financing services and trading in China, asset management business in Hong Kong, and cross-border money transfer services in the United Kingdom. It has also expanded into brokerage and investment banking business in Hong Kong and a cryptocurrency mining farm in the U.S. The company's reportable segments include asset management services, supply chain financing and trading, and others.

About JAGX Jaguar Health Inc.

Jaguar Health Inc is a commercial-stage pharmaceuticals company focused on developing novel, plant-based, non-opioid, and sustainably derived prescription medicines for people and animals with GI distress, specifically chronic, debilitating diarrhea. Its product Mytesi is a novel, first-in-class anti-secretory agent which has a basic normalizing effect locally on the gut, and this mechanism of action has the potential to benefit multiple disorders. It has two reportable segments namely human health and animal health. The company generates the majority of its revenue from the Human Health segment.

Share on Social Networks: